Medical Licensing (MD/DO) · Independent exam preparation
Addiction Medicine Certification Examination Study Guide
Practise diagnosis, screening, withdrawal triage, addiction pharmacology, prevention calculations, treatment selection, and confidentiality decisions for ABPM physician subspecialty certification.
By CertMedbry · Updated 16 October 2026
Learn to diagnose and grade alcohol use disorder, move from screening to appropriate intervention, distinguish dangerous withdrawal from uncomplicated symptoms, select treatment using pharmacology and comorbidity, interpret prevention evidence, and protect patient autonomy and confidentiality. This selective guide contains 60 concepts: 15 foundations, 12 epidemiology and prevention, 24 assessment and management, and 9 ethics and law. These proportions follow the four published content-group weights. The official ABPM Addiction Medicine content outline defines the full examination scope; this guide cannot cover every listed substance, disorder, or clinical presentation.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and pathway does this guide address?
It addresses the American Board of Preventive Medicine Addiction Medicine initial certification examination, a physician subspecialty examination. The currently posted pathway requires completion of an ACGME-accredited Addiction Medicine fellowship, alongside the applicable medical degree, unrestricted license, and primary specialty certification requirements. ABPM specifies at least 12 months of fellowship and completion of all accredited years when a program is longer.
How do Canadian qualifications fit this examination?
ABPM lists qualifying Canadian medical licenses and primary certifications among its general eligibility provisions. Those provisions do not create a separate Canadian examination or establish a different jurisdiction's credential. Qualifying Canadian general credentials do not themselves substitute for the currently posted ACGME-accredited fellowship pathway requirements.
How many questions are there, and how much time is allowed?
ABPM lists 200 questions delivered in four one-hour blocks. The total appointment is four hours and 30 minutes, including a 15-minute tutorial and a 15-minute break. The 2026 Program Director Guide corroborates the 200-question, 4.5-hour format.
Which item styles, scoring rules, and review rules apply?
ABPM describes multiple-choice, single-best-answer questions with four or five responses. Questions may use clinical vignettes, epidemiological observations, classifications, administrative problems, or applications of principles and regulations. Questions carry equal weight, and incorrect answers incur no subtraction. The examination is closed-book. Candidates may review answers within the current block but cannot return after leaving it or after its time expires.
How should these practice questions be used?
Use the 20 original four-option questions to identify reasoning gaps and practise choosing the single best response. Their domain distribution is five foundations, four epidemiology and prevention, eight clinical management, and three ethics and law. This small set follows the published content-group proportions but cannot reproduce the full substance distribution or predict a passing examination score.
ABPM — Exam Content · ABPM — Addiction Medicine Content Outline
Which blueprint applies, and does it have a stated effective date?
The currently posted outline assigns 25% to topics 01–05, 20% to topics 06–08, 40% to topics 09–16, and 15% to topic 17. It displays no revision number or effective date. ABPM's 2026 guide links to this outline. The July 2025 practice-analysis announcement describes revision work but supplies no replacement blueprint or implementation date. The four domain labels used here summarize those official numbered groups.
ABPM — Addiction Medicine Content Outline · ABPM — 2026 Program Director Guide · ABPM — Addiction Medicine Practice Analysis Survey Underway
How should the separate substance targets influence preparation?
ABPM separately lists alcohol and nicotine at 15–20% each; opioids at 10–15%; sedatives, stimulants, and cannabinoids at 7–10% each; hallucinogens, dissociatives, inhalants, and anabolic steroids at 0.5–3% each; other substances and nonsubstance addiction at 1–3% each; and general/all substances combined at 1–5%. These are a second blueprint axis, not additional domain percentages. This selective guide and its 20-item sets do not reproduce every substance target.
Does this examination include core preventive medicine content?
ABPM states that subspecialty examinations contain subspecialty-specific content without a separate core preventive medicine component. Epidemiology and prevention remain substantial Addiction Medicine content because they are explicitly included in its own outline.
ABPM — Exam Content · ABPM — Addiction Medicine Content Outline
What 2026 examination window is documented?
The 2026 Program Director Guide identifies an October 12–November 1, 2026 examination window. This is cycle-specific scheduling information and should not be generalized to another year.
This is independent CertMedbry educational material for physician subspecialty certification in Addiction Medicine. Its practice questions and flashcards are original learning exercises. They do not establish examination readiness or imply ABPM endorsement.
Outline used: Current ABPM Addiction Medicine Content Outline, accessed 2026-10-09. The live outline states no revision number or effective date. ABPM's 2026 Program Director Guide links to this outline for initial certification. The assigned workbook label maps to ABPM's Addiction Medicine subspecialty certification examination; the assigned slug is preserved. No separately dated 2026 blueprint is implied.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Foundations (01–05)25%
1.How does physical dependence differ from a substance use disorder?
Physical dependence is physiological adaptation that can produce withdrawal when a medication is reduced or stopped. It can develop during appropriate prescribed treatment and does not, by itself, establish a substance use disorder. A disorder requires a broader pattern of problematic use and associated impairment or distress. For benzodiazepines, distinguish expected adaptation from behaviors such as impaired control and continued use despite harm before assigning a diagnosis or changing treatment.
Apply it
A patient taking a stable prescribed benzodiazepine develops tremor after missed doses but reports no escalation, compulsive use, or functional harm. Assess physical dependence and plan a safe taper if indicated rather than diagnosing addiction from withdrawal alone.
Common pitfall: Withdrawal demonstrates adaptation, not necessarily compulsive use. Conversely, an appropriate prescription does not exclude a disorder when impaired control and harmful use are present.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
2.How is ethanol converted into acetate?
Alcohol dehydrogenase converts ethanol to acetaldehyde, and aldehyde dehydrogenase converts acetaldehyde to acetate. Acetaldehyde is a toxic intermediate rather than the harmless endpoint of alcohol metabolism. Other pathways, including CYP2E1, also contribute to ethanol oxidation. When interpreting an adverse alcohol response, identify whether the problem concerns ethanol exposure, formation of acetaldehyde, or impaired clearance of acetaldehyde; these represent different mechanisms and should not be treated as interchangeable.
Apply it
A learner attributes alcohol-associated flushing to accumulated acetate. Trace the sequence explicitly: ethanol becomes acetaldehyde, then acetate. The intermediate that accumulates with reduced aldehyde dehydrogenase activity is acetaldehyde, which explains the adverse reaction.
Common pitfall: Do not reverse alcohol dehydrogenase and aldehyde dehydrogenase. Their similar names conceal different substrates and different consequences when enzyme activity is reduced.
3.Why can inherited alcohol flushing signal increased harm?
Reduced ALDH2 activity slows acetaldehyde clearance after alcohol consumption. Accumulation can cause flushing, nausea, and palpitations. The reaction is an inherited metabolic intolerance rather than evidence that alcohol is being eliminated especially efficiently. Continuing to drink despite this response increases exposure to carcinogenic acetaldehyde and is associated with elevated risk of certain cancers, including esophageal cancer. Symptom suppression does not correct the underlying metabolic defect or eliminate that exposure.
Apply it
A patient who flushes after small amounts of alcohol asks whether an antihistamine would make drinking safe. Explain that hiding visible flushing does not restore acetaldehyde metabolism and should not be interpreted as protection from alcohol-related harm.
Common pitfall: Flushing may discourage drinking, but it is not a protective shield for someone who continues drinking. Less visible redness does not mean less acetaldehyde exposure.
4.How do inherited susceptibility and environment influence alcohol use disorder risk?
Alcohol use disorder has a substantial inherited component, but susceptibility is polygenic rather than determined by a single diagnostic gene. Genetic influences interact with developmental, social, and environmental exposures, including stress and alcohol availability. Family history changes the assessment of vulnerability without establishing a current diagnosis or an inevitable outcome. Family clustering can reflect both shared genes and shared circumstances. Assess inherited susceptibility alongside modifiable exposures, supports, and current symptoms.
Apply it
Two siblings with a strong family history have different drinking patterns after prolonged exposure to different social environments. Explore stress, availability, coping, and supports alongside inherited vulnerability rather than expecting identical outcomes.
Common pitfall: A positive family history is neither a diagnosis nor a deterministic forecast. Different outcomes among relatives do not exclude genetic influence, and family clustering does not isolate a genetic cause.
5.How is alcohol use disorder diagnosed and graded?
AUD requires a problematic pattern causing clinically significant impairment or distress, with at least two of eleven symptoms within twelve months. The symptoms are drinking more or longer than intended; unsuccessful efforts to cut down; substantial time obtaining, using, or recovering; craving; failure of major obligations; continued use despite interpersonal problems; reduced important activities; hazardous use; continued use despite a known related physical or psychological problem; tolerance; and withdrawal or drinking to avoid it. Severity is mild with two or three symptoms, moderate with four or five, and severe with six or more.
Apply it
During the same twelve months, a patient repeatedly drinks more than intended, unsuccessfully tries to cut down, experiences craving, and misses work because of drinking. These are four distinct symptoms, supporting moderate AUD when the overall impairment or distress requirement is met.
Common pitfall: Drinking quantity and a screening score do not determine AUD severity. Count distinct diagnostic symptoms within the specified period; tolerance and withdrawal are not required for diagnosis.
6.Why does sublingual administration matter for buprenorphine?
The route of administration changes how much active buprenorphine reaches systemic circulation. Sublingual tablets are intended to dissolve under the tongue, permitting absorption through oral mucosa. Swallowing the tablet instead exposes drug to gastrointestinal absorption and extensive first-pass metabolism, reducing effective delivery compared with intended use. When a patient reports inadequate effect, assess administration technique alongside dose, adherence, interactions, and ongoing opioid exposure before concluding that the medication itself has failed.
Apply it
A patient has been swallowing each sublingual tablet immediately and reports persistent withdrawal. Review how the product should dissolve under the tongue, then reassess response and other contributors before assuming that the prescribed amount is ineffective.
Common pitfall: Identical milligram amounts do not guarantee equivalent exposure across routes. Do not solve an administration problem by reflexively escalating treatment without checking technique first.
DailyMed — Buprenorphine Sublingual Tablets Prescribing Information
7.Why can oral cannabinoids produce delayed and prolonged effects?
Oral dronabinol undergoes substantial first-pass metabolism and forms an active metabolite, 11-hydroxy-THC. Oral effects develop later than many users expect and can persist after the initial dosing decision. This creates a risk of taking additional doses before the first dose has fully acted. The useful distinction is between delayed absorption and true absence of drug effect; early subjective nonresponse does not establish that an oral cannabinoid exposure was clinically insignificant.
Apply it
A patient takes another oral cannabinoid product soon after the first because nothing seems to happen, then develops marked impairment later. Explain the delayed oral time course and active metabolism that make early repeated dosing unreliable.
Common pitfall: Do not transfer expectations from inhaled exposure directly to oral products. The dronabinol label supports its pharmacology, not identical timing for every commercial edible.
8.What does partial mu-opioid agonism explain about buprenorphine?
Buprenorphine activates mu-opioid receptors with lower intrinsic activity than full agonists while binding strongly to those receptors. This combination can suppress withdrawal and craving yet also displace other opioids. Partial agonism does not mean absence of opioid effects, dependence, or respiratory risk. Its safety advantages must be interpreted alongside concomitant sedatives, respiratory disease, and administration circumstances rather than converted into a claim that overdose or clinically important sedation cannot occur.
Apply it
A patient believes that a partial agonist cannot cause dangerous sedation when combined with alcohol. Explain that buprenorphine remains an opioid and that other central nervous system depressants can increase respiratory and sedation risks despite partial agonism.
Common pitfall: A ceiling in some pharmacologic effects is not universal protection. Co-exposures and patient vulnerability remain important, especially with alcohol, benzodiazepines, or other sedating drugs.
DailyMed — Buprenorphine Sublingual Tablets Prescribing Information
9.How can buprenorphine precipitate opioid withdrawal?
Buprenorphine can displace a full mu-opioid agonist because of its high receptor affinity. If substantial full-agonist activity remains, replacement by a drug with lower intrinsic activity can abruptly reduce net receptor stimulation and trigger withdrawal. The discriminating pattern is a rapid worsening shortly after initiation in an opioid-dependent patient. For standard induction, clinical evidence of withdrawal helps determine readiness; elapsed time alone is an imperfect substitute for assessment.
Apply it
An opioid-dependent patient takes buprenorphine while still comfortable after recent full-agonist use and develops abrupt vomiting, sweating, and agitation. Receptor displacement with reduced net agonism explains the sudden worsening more directly than ordinary gradual withdrawal.
Common pitfall: High receptor affinity does not mean stronger receptor activation. Confusing affinity with intrinsic activity obscures why an effective treatment can precipitate withdrawal during initiation.
DailyMed — Buprenorphine Sublingual Tablets Prescribing Information
10.Which cannabinoid effects matter beyond the desired treatment response?
Dronabinol can impair cognition and mental or physical performance and can worsen mania, depression, or schizophrenia. Its label advises screening for psychiatric history and avoiding use in patients with such a history when possible; if treatment is necessary, monitor closely for new or worsening symptoms. Alcohol and other central nervous system depressants can add sedation and impairment. A therapeutic indication therefore does not eliminate the need to assess psychiatric vulnerability, interacting exposures, and activities requiring alertness.
Apply it
Before prescribing dronabinol to a patient with prior mania, review the psychiatric course and current sedatives. Discuss the risk of psychiatric worsening and impaired performance, consider alternatives, and establish monitoring if treatment proceeds. New confusion or marked mood changes should prompt reassessment.
Common pitfall: Do not interpret reduced nausea or improved appetite as proof of overall tolerability. Desired effects can coexist with cognitive impairment, additive sedation, or worsening psychiatric symptoms.
11.How does varenicline reduce smoking reinforcement?
Varenicline binds to nicotine receptors and partially activates them, helping reduce craving and withdrawal while reducing nicotine's rewarding effects if smoking occurs. It supplies no nicotine. This differs from nicotine replacement, which provides nicotine through a less harmful delivery route than combustible cigarettes. Recognizing receptor action helps explain why a medication can both ease cessation symptoms and make a lapse feel less rewarding without functioning as an opioid antagonist or a sedative.
Apply it
A smoker asks whether varenicline is simply another nicotine product. Explain that it acts at nicotine receptors without supplying nicotine, whereas a patch delivers nicotine to reduce withdrawal through a different pharmacologic approach.
Common pitfall: Do not confuse receptor binding with nicotine replacement. Varenicline's action also does not guarantee that cravings disappear or that behavioral support becomes unnecessary during cessation.
12.Why can nicotine replacement help while reducing smoke exposure?
Nicotine replacement supplies nicotine to reduce withdrawal and craving while avoiding the toxic products generated by burning tobacco. The treatment principle separates the reinforcing drug from the particularly harmful delivery system. A patch provides a steady background supply, while gum or lozenges can address episodes of craving. This distinction supports cessation counseling that acknowledges nicotine dependence without implying that medicinal nicotine and continued cigarette smoking carry equivalent overall health risks.
Apply it
A patient refuses a nicotine patch because cigarettes also contain nicotine. Explain that the patch treats withdrawal without exposing the lungs to combustion products, then discuss how medication and behavioral strategies can support the attempt to stop smoking.
Common pitfall: Nicotine dependence matters, but equating all nicotine delivery with smoking can deter effective treatment. Replacement is a cessation aid, not proof that tobacco exposure is harmless.
CDC — How Quit Smoking Medicines Work · CDC — How to Combine Quit Smoking Medicines
13.What role do the basal ganglia play in the addiction cycle?
NIAAA links the binge/intoxication stage of the addiction cycle to basal ganglia circuits involved in reward, reinforcement, and habit formation. Repeated substance exposure can strengthen associations between cues, actions, and rewarding effects. Over time, familiar contexts may provoke strong urges even when a person explicitly intends to abstain. This model helps explain cue-driven repetition without reducing addiction to pleasure seeking alone or assuming that conscious knowledge automatically overrides learned responses.
Apply it
A patient develops intense urges when passing a former drinking venue despite having felt well earlier that day. Use learned cue–reward associations to explain the reaction and identify practical changes to routines and responses.
Common pitfall: A strong cue response does not prove that treatment has failed. It identifies a learned vulnerability that can be addressed through planning and behavioral treatment.
14.Why can substance use continue after its pleasurable effects diminish?
The withdrawal/negative-affect stage involves stress-related circuitry associated with the extended amygdala. As addiction progresses, substance use may increasingly relieve distress rather than primarily create pleasure. This is negative reinforcement: removal of an aversive state strengthens the behavior that produced relief. The distinction helps explain continued use despite reduced enjoyment and supports treatment that addresses withdrawal, stress, sleep, and emotional regulation alongside efforts to reduce access to rewarding substance effects.
Apply it
A patient says alcohol is no longer enjoyable but temporarily quiets an unbearable anxious state between drinking episodes. Identify relief of distress as negative reinforcement and assess withdrawal and continuing treatment needs rather than assuming simple pleasure seeking.
Common pitfall: Negative reinforcement means strengthening behavior by removing distress. It does not mean punishment, and loss of pleasure does not establish that compulsive use has resolved.
15.How does prefrontal dysfunction affect recovery decisions?
NIAAA associates the preoccupation/anticipation stage with prefrontal circuits involved in executive functions such as planning, decision-making, and inhibitory control. Disruption can make it harder to resist immediate urges despite understanding delayed consequences. Treatment planning can compensate through structured routines, accessible support, and rehearsed responses to high-risk situations. Recognizing impaired control explains why factual knowledge about harm may coexist with repeated use and why recovery requires more than additional information.
Apply it
A patient accurately describes alcohol-related harm yet repeatedly abandons an evening abstinence plan when cravings arise. Build concrete routines, support contacts, and behavioral practice instead of assuming that another explanation of medical risks will solve the problem.
Common pitfall: Understanding a consequence and consistently controlling behavior are different capacities. Avoid interpreting every recurrence of use as evidence that the patient never understood the risks.
Epidemiology and prevention (06–08)20%
16.How is cumulative incidence calculated?
Cumulative incidence measures the proportion of an initially disease-free population that develops the condition during a specified interval. Divide new cases by the population at risk at the start, with appropriate attention to follow-up and eligibility. Existing cases do not belong in the numerator or the population susceptible to a first event. The time interval is essential: a five-year risk cannot be interpreted as though it were an annual risk.
Apply it
A closed cohort begins with 800 people free of the disorder, and 40 develop it during one year with complete follow-up. The one-year cumulative incidence is 40 divided by 800, or 5%.
Common pitfall: Counting everyone currently affected produces prevalence rather than incidence. Always identify new cases, the susceptible denominator, and the observation period before performing the calculation.
CDC — Principles of Epidemiology, Morbidity Frequency Measures
17.What does point prevalence measure?
Point prevalence is the proportion of a population with a condition at a specified time. It includes existing cases regardless of when they began, making it useful for estimating current service needs. It does not directly measure the rate at which new cases arise. Interpretation depends on the case definition and population sampled; a treatment-clinic census cannot automatically estimate prevalence in the surrounding community because referral and access shape who appears there.
Apply it
On a census date, 90 of 1,500 surveyed residents meet the specified current case definition. Point prevalence is 6%. The result describes current burden in that sampled population, not the number newly affected during the year.
Common pitfall: A prevalence numerator includes old and new existing cases. Do not call it annual incidence merely because the survey happens to be repeated each year.
CDC — Principles of Epidemiology, Morbidity Frequency Measures
18.Why can prevalence rise when incidence stays stable?
Prevalence reflects both the occurrence of new cases and how long people remain cases. Longer survival or longer duration of an active condition can increase the number living with it even when new-case occurrence is unchanged. Conversely, shorter duration can lower prevalence without demonstrating prevention success. When interpreting a trend, examine incidence, recovery, mortality, and case-definition changes rather than treating prevalence as a direct measure of new disease development.
Apply it
A community reports stable new-case incidence but increasing numbers of residents living with a chronic substance-related condition. Longer survival could explain the higher prevalence, so the trend alone does not show that prevention has become less effective.
Common pitfall: Higher prevalence is not automatically evidence of rising incidence. Improved survival may increase measured burden even while an important aspect of clinical care is improving.
CDC — Principles of Epidemiology, Morbidity Frequency Measures
19.How should a risk ratio be interpreted?
A risk ratio divides risk in the exposed group by risk in the comparison group over a defined interval. A value of one indicates equal observed risks; values above or below one indicate higher or lower relative risk. The measure does not describe absolute burden by itself and does not establish causation. Interpretation requires the underlying risks, comparable outcome definitions, and attention to confounding, selection, and measurement differences between the groups.
Apply it
During equal follow-up, 30 of 300 exposed participants and 10 of 300 comparison participants develop an outcome. Risks are 10% and approximately 3.3%; the risk ratio is three, indicating threefold observed risk.
Common pitfall: A risk ratio of three does not mean a three-percentage-point increase. Relative comparison and absolute difference answer different questions and require separate calculations.
20.Why calculate an absolute risk difference?
An absolute risk difference subtracts one group's risk from another's using the same outcome and follow-up interval. It expresses the excess or reduction in events per population rather than a proportional comparison. Two interventions can have similar relative effects but very different absolute benefits when baseline risks differ. Absolute measures therefore help translate epidemiological findings into expected service needs and prevention impact, while still requiring assessment of study validity before causal conclusions.
Apply it
An intervention group has a 4% event risk and a comparison group has a 10% risk over one year. The absolute reduction is six percentage points, equivalent to six fewer events per 100 people over that interval.
Common pitfall: Subtract percentages as percentage points. Describing a reduction from 10% to 4% as a 6% relative reduction confuses absolute and proportional changes.
21.When is an odds ratio appropriate?
A case-control study usually selects participants according to outcome status, so its sampled case fraction does not provide population disease risk. The odds ratio compares exposure odds among cases with exposure odds among controls. For a two-by-two table, it is the cross-product ratio. It can approximate a risk ratio under suitable conditions, including a rare outcome, but odds and risks remain different quantities and should not be casually described as equivalent.
Apply it
Investigators select people with an overdose outcome and controls without it, then compare prior exposure. Because the numbers of cases and controls were chosen by design, calculate an exposure odds ratio rather than deriving population incidence from their proportions.
Common pitfall: The proportion of cases in a case-control sample is determined partly by sampling. It cannot be used as the population's outcome risk or prevalence.
22.How does study design affect temporal interpretation?
A cross-sectional assessment measures exposure and outcome at roughly the same time and is well suited to estimating prevalence. It may leave unclear whether the exposure preceded the outcome. A cohort follows people over time and can measure incident outcomes after exposure classification. Temporal order strengthens interpretation but does not eliminate confounding. Choose the design and measure that match the question rather than assigning causal meaning to any observed association.
Apply it
A one-time survey finds an association between distress and substance use. Because both were measured together, the study cannot establish whether distress preceded use, followed it, or shares another cause with it in the sampled population.
Common pitfall: An association measured at one visit does not establish direction. Even prospective follow-up requires attention to confounding and the accuracy of exposure and outcome measurement.
CDC — Principles of Epidemiology, Morbidity Frequency Measures · CDC — Principles of Epidemiology, Measures of Association
23.How should age-specific and sex-specific AUD estimates guide interpretation?
NIAAA summarizes a 2023 national survey as finding that about one in seven men, one in eleven women, and one in thirty-three adolescents aged twelve through seventeen met AUD diagnostic criteria. These estimates describe disorder burden in specified populations during the survey's reference period. They are not incidence measures, treatment-enrollment rates, or estimates of fatal overdose. Preserve the population, year, and case definition when comparing groups or planning services, and distinguish population estimates from an individual patient's diagnosis.
Apply it
A service planner can use the estimates to recognize that AUD affects adults and adolescents and to support routine screening. An adolescent's lower population prevalence does not justify omitting assessment when symptoms or a positive screen warrant it.
Common pitfall: One year's survey estimates do not establish a trend or explain why groups differ. Do not compare estimates with different age ranges, diagnostic definitions, or reference periods as though they measured the same population.
Alcohol Use Disorder: From Risk to Diagnosis to Recovery | National Institute on Alcohol Abuse and Alcoholism (NIAAA) · CDC — Principles of Epidemiology, Morbidity Frequency Measures
24.Which primary-care intervention helps prevent youth tobacco initiation?
The USPSTF recommends primary-care interventions, including education or brief counseling, to prevent tobacco use initiation among school-aged children and adolescents. The prevention recommendation includes consideration of electronic cigarettes. The clinical target is a young person who has not begun use, and counseling should address initiation rather than assuming an established dependence requiring cessation medication. Prevention evidence and cessation evidence must be evaluated separately because they address different populations and outcomes.
Apply it
A 14-year-old who has never used tobacco reports that friends are encouraging vaping. Provide brief prevention counseling about nicotine products and strategies for responding to pressure rather than waiting until regular use or dependence develops.
Common pitfall: Do not restrict prevention counseling to combustible cigarettes. Also avoid applying adult cessation medication recommendations automatically to a tobacco-naive adolescent seeking prevention advice.
USPSTF — Tobacco Use in Children and Adolescents: Primary Care Interventions
25.What does insufficient youth cessation evidence mean?
The USPSTF finds insufficient evidence to determine the balance of benefits and harms of primary-care cessation interventions for school-aged children and adolescents who already use tobacco. An insufficient-evidence statement does not establish that intervention is ineffective or harmful. It identifies uncertainty in the evidence base. Distinguish that conclusion from the affirmative prevention recommendation, and approach an individual young person's dependence, preferences, family context, and clinical needs without claiming unsupported certainty.
Apply it
A clinician reads the youth cessation statement and concludes that adolescents should receive no help quitting. Correct the interpretation: insufficient evidence does not prove no benefit, and it differs from the recommendation supporting prevention of initiation.
Common pitfall: An evidence gap is not a recommendation to ignore dependence. Avoid converting uncertainty into either a guaranteed treatment benefit or a blanket prohibition on care.
USPSTF — Tobacco Use in Children and Adolescents: Primary Care Interventions
26.Why use needs-based syringe distribution?
Needs-based syringe distribution aims to provide enough sterile equipment for each injection rather than making access depend on returning an identical number of used syringes. Restrictive exchange requirements can leave people without sufficient sterile supplies. Safe disposal remains an important program service, but it should support rather than undermine prevention access. The public-health mechanism is reduction of equipment sharing and reuse, alongside opportunities to connect participants with additional health and treatment services.
Apply it
A participant has no used syringes to return after losing belongings but expects ongoing injection. Provide supplies according to need and offer disposal options, rather than using a rigid return requirement that leaves anticipated injections uncovered.
Common pitfall: One-for-one exchange may appear administratively fair yet fail to provide adequate sterile coverage. Disposal goals should not become a barrier that increases preventable exposure.
27.How do syringe services connect prevention with treatment?
Comprehensive syringe services extend beyond equipment distribution to safer disposal, overdose prevention, infectious-disease services, vaccination, and linkage to substance use treatment and other care. These services address multiple pathways of harm while creating repeated opportunities for engagement. Sterile equipment access does not require a participant first to achieve abstinence. The practical distinction is between reducing immediate exposure and treating the underlying disorder; effective programs can support both goals at the same time.
Apply it
A person seeking sterile equipment is also concerned about an injection-related infection and recent overdoses among friends. Offer wound-care linkage, testing and vaccination services, overdose prevention, and treatment access while meeting the immediate equipment need.
Common pitfall: Do not make treatment enrollment a prerequisite for prevention services. Immediate risk reduction and voluntary engagement in treatment can proceed together at the participant's pace.
Assessment and clinical management (09–16)40%
28.How should alcohol screening lead to assessment and intervention?
Use a validated adult screener such as AUDIT-C or the NIAAA Single Alcohol Screening Question: how many times in the past year the patient had at least four drinks in a day for women or five for men. One or more occasions warrants follow-up. AUDIT-C assesses drinking frequency, typical quantity, and heavy occasions. A positive screen identifies possible unhealthy use; assess the weekly pattern, eleven AUD symptoms, withdrawal risk, and medical or psychiatric consequences before selecting care. Brief intervention includes personalized feedback, advice, a negotiated goal, and follow-up. AUD requires consideration of continuing behavioral treatment, medication, and recovery support.
Apply it
A man reports two five-drink days during the past year, producing a positive single-question screen. If assessment finds no AUD symptoms or withdrawal risk, offer brief advice and agree on a reduction goal with follow-up. If he instead reports four AUD symptoms, diagnose moderate AUD and discuss ongoing treatment as well as immediate safety.
Common pitfall: Screening is not diagnosis, and a positive screen does not automatically require withdrawal treatment. A brief conversation alone is insufficient treatment planning for established AUD.
Screen and Assess: Use Quick, Effective Methods | National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Alcohol Use Disorder: From Risk to Diagnosis to Recovery | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
29.Which history predicts complicated alcohol withdrawal?
Previous alcohol withdrawal delirium or seizures is an important predictor of future complicated withdrawal. Repeated withdrawal episodes, substantial physiological dependence, acute medical illness, and concurrent sedative dependence can further increase concern. Current mild symptoms do not erase these risks. Assessment should distinguish present severity from the likelihood of deterioration, because disposition and preventive treatment depend on both. A reassuring appearance early after reduction may precede a dangerous subsequent course.
Apply it
A patient has only mild tremor several hours after stopping alcohol but previously required intensive treatment for withdrawal delirium. Use the prior complication to inform monitoring and treatment planning rather than assuming the current score establishes low risk.
Common pitfall: Present symptom severity and future complication risk are different judgments. A low initial score does not neutralize a history of withdrawal seizures or delirium.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
30.How is the setting for alcohol withdrawal care selected?
Withdrawal setting depends on expected severity, previous complications, medical and psychiatric stability, available monitoring, and the recovery environment. Ambulatory treatment requires more than the absence of severe symptoms at one visit; patients need a feasible plan for reassessment and escalation. Unstable illness, severe or complicated withdrawal, or inadequate support can require a higher level of care. Match the setting to the whole risk picture rather than selecting it from drinking quantity alone.
Apply it
A patient with emerging withdrawal also has an unstable medical condition and no reliable way to return for monitoring. The combination supports a more closely monitored setting even if symptoms have not yet reached their maximum severity.
Common pitfall: Outpatient care is not determined solely by patient preference or a single symptom score. Monitoring capability and co-occurring instability can change the appropriate disposition.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
31.How can alcohol withdrawal occur with a positive blood alcohol level?
Alcohol withdrawal follows a reduction in alcohol exposure relative to an adapted baseline, not necessarily complete elimination of alcohol from blood. A dependent person can develop withdrawal while the measured level remains positive, particularly during a rapid decline from a higher usual exposure. Assess the clinical pattern and reduction history rather than using a positive level to exclude withdrawal. At the same time, intoxication, other substances, and medical illness may coexist and require evaluation.
Apply it
A highly tolerant patient develops tremor and autonomic symptoms as alcohol intake falls, although a blood test still detects ethanol. Consider withdrawal alongside other causes rather than postponing assessment until the laboratory result becomes negative.
Common pitfall: A positive blood alcohol result does not distinguish uncomplicated intoxication from withdrawal risk. Physiological adaptation and change in exposure matter more than a binary result.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
32.Why are benzodiazepines central to alcohol withdrawal treatment, and how should the agent and regimen be selected?
Benzodiazepines enhance GABA-A-mediated inhibition through positive allosteric modulation of the receptor. This strengthens inhibitory signaling during withdrawal-related neuronal hyperexcitability, explaining their ability to reduce withdrawal symptoms, seizures, and delirium. In significant liver disease, prefer an agent less dependent on hepatic oxidative metabolism, such as lorazepam or oxazepam, to reduce accumulation risk. Symptom-triggered dosing is preferred when trained staff can perform reliable, repeated assessments. When reliable symptom assessment is infeasible, an appropriately monitored scheduled regimen can be used, with reassessment and additional medication for breakthrough withdrawal.
Apply it
For a hospitalized patient with alcohol withdrawal and significant liver disease, lorazepam offers an advantage over agents with prolonged oxidative metabolism and active metabolites. If the patient can communicate reliably and trained staff can reassess frequently, use symptom-triggered treatment. If communication prevents reliable scoring, use a monitored regimen that does not depend solely on patient-reported symptoms. Reassess withdrawal severity, alertness, respiratory rate, and oxygenation throughout treatment.
Common pitfall: Reduced tachycardia does not establish seizure protection: medications that suppress autonomic signs can conceal persistent withdrawal-related hyperexcitability. Scheduled dosing still requires monitoring and adjustment. Watch for oversedation and respiratory depression, particularly with other CNS depressants, and reassess the dose and level of care when either develops.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
33.When are alpha-2 agonists adjuncts in alcohol withdrawal?
Alpha-2 adrenergic agonists can help control persistent autonomic hyperactivity and anxiety when used as adjuncts to appropriate alcohol withdrawal treatment. They do not provide the seizure or delirium protection expected from adequate primary withdrawal pharmacotherapy. Their role is therefore supplementary rather than a replacement for treatment of the underlying withdrawal syndrome. Reassess the patient when autonomic signs improve, because a quieter pulse and blood pressure can make continuing withdrawal less visible.
Apply it
A patient's tachycardia improves after an alpha-2 agonist, but tremor and other withdrawal findings persist. Continue assessing the adequacy of primary withdrawal treatment rather than concluding that normalized vital signs have removed seizure risk.
Common pitfall: Autonomic suppression is not comprehensive withdrawal treatment. Using an adjunct alone can mask severity while leaving the patient vulnerable to seizures or withdrawal delirium.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
34.How should thiamine and urgent glucose be coordinated?
Thiamine helps prevent or treat complications related to deficiency in patients at risk during alcohol withdrawal care. Parenteral administration is especially relevant with poor nutritional status, malabsorption, or severe illness. Urgent treatment of hypoglycemia should not be delayed while waiting for thiamine; ASAM permits thiamine and glucose in either order or concurrently. Address both needs promptly, distinguishing a useful preventive measure from a reason to withhold immediately necessary metabolic resuscitation.
Apply it
A malnourished patient with heavy alcohol exposure is confused and hypoglycemic, and thiamine is not immediately at the bedside. Treat hypoglycemia promptly and arrange thiamine without making access to thiamine a prerequisite for glucose.
Common pitfall: A rigid rule requiring thiamine before every glucose dose can delay lifesaving care. Correct the urgent glucose deficit while also addressing the patient's deficiency risk.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
35.Which tools replace CIWA-Ar when alcohol withdrawal is complicated by delirium?
CIWA-Ar relies partly on patient-reported symptoms and is not recommended during delirium. ASAM recommendation VI.9 names alternatives including CAM-ICU, DDS, RASS, and MINDS. Their functions differ: CAM-ICU assesses delirium, whereas RASS measures agitation and sedation and helps monitor treatment effects. MINDS provides structured withdrawal monitoring with less reliance on verbal reporting. Combine suitable tools with objective examination, vital signs, respiratory monitoring, and investigation of other delirium causes. A withdrawal scale alone neither establishes the diagnosis nor excludes infection, pain, medication effects, or another illness.
Apply it
A disoriented patient cannot reliably describe anxiety or sensory disturbances. Use CAM-ICU to assess delirium, RASS to follow agitation and sedation, and an appropriate objective withdrawal protocol such as MINDS while evaluating alternative or additional causes.
Common pitfall: A reassuring agitation score does not demonstrate that delirium has resolved. Delirium assessment, withdrawal severity assessment, and sedation monitoring answer different clinical questions.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
36.Why must withdrawal management lead into ongoing treatment?
Alcohol withdrawal management addresses an acute physiological syndrome; it does not by itself treat the continuing disorder that led to repeated harmful use. Once cognitive status permits, use the episode to engage the patient in ongoing care, including appropriate medication, behavioral treatment, and recovery support. A completed withdrawal course should therefore be viewed as a transition point. Persistent craving, environmental triggers, and recurrent use risk remain relevant after vital signs and tremor normalize.
Apply it
A patient's withdrawal resolves and discharge planning consists only of stopping the acute medication. Add a discussion of ongoing alcohol use disorder treatment, appropriate medication options, and a concrete connection to continuing care before discharge.
Common pitfall: Successful detoxification does not establish remission or durable recovery. Repeating withdrawal care without addressing ongoing treatment needs leaves the central disorder insufficiently managed.
ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
37.What opioid history and abstinence interval are required before oral naltrexone?
Naltrexone is an opioid receptor antagonist. It is contraindicated with current opioid analgesic treatment, physiological opioid dependence, or acute opioid withdrawal. The oral label recommends a minimum opioid-free interval of seven to ten days after dependence on short-acting opioids, including tramadol. Patients transitioning from methadone or buprenorphine can remain vulnerable to precipitated withdrawal for up to two weeks. Assess exposure history, examination, and testing as appropriate: elapsed time, a negative urine test, or even a tolerated naloxone challenge cannot guarantee readiness.
Apply it
A patient who stopped short-acting opioids three days ago is not ready merely because a urine test is negative. A patient ten days after buprenorphine cessation may also remain vulnerable. Neither should be cleared for naltrexone using the calendar or screening result alone.
Common pitfall: The alcohol indication does not remove opioid contraindications. These intervals guide assessment; they are not guarantees that antagonist initiation will be free of precipitated withdrawal.
DailyMed — Naltrexone Hydrochloride Tablets Prescribing Information
38.Which renal findings determine acamprosate dosing or exclusion?
Acamprosate supports maintenance of alcohol abstinence in patients abstinent at initiation, alongside psychosocial care. The usual regimen is 666 mg three times daily. For moderate renal impairment, labeled as creatinine clearance 30–50 mL/min, the reduced regimen is 333 mg three times daily. The separate contraindication at creatinine clearance of 30 mL/min or less takes precedence at the boundary: a clearance of exactly 30 is contraindicated, so the reduced regimen applies above 30 through 50 mL/min. Acamprosate does not treat acute withdrawal.
Apply it
An abstinent patient with creatinine clearance of 40 mL/min can be considered for 333 mg three times daily if otherwise appropriate. A comparable patient with clearance of 24 mL/min cannot receive acamprosate because severe renal impairment is contraindicated.
Common pitfall: Do not apply dose reduction to a clearance of 30 mL/min or less. Matching the abstinence indication does not override the renal contraindication.
39.How is readiness for standard buprenorphine initiation assessed?
For standard sublingual buprenorphine initiation, evaluate the opioid used, recent exposure, physiological dependence, and objective withdrawal findings. Beginning while substantial full-agonist effects remain can precipitate withdrawal because buprenorphine displaces the agonist while providing less receptor activation. A fixed elapsed-time rule alone cannot account for different opioids and exposure patterns. The clinical decision centers on readiness for the selected induction approach, with reassessment and an appropriate plan for monitoring response.
Apply it
A patient requests the first buprenorphine dose after recent full-agonist use but has no objective withdrawal. Reassess readiness and the planned initiation approach rather than assuming that the patient's request alone establishes a safe moment for standard induction.
Common pitfall: Time since last use is useful history, not a complete assessment. Different opioid exposures and persistent agonist effects can make a clock-only decision misleading.
DailyMed — Buprenorphine Sublingual Tablets Prescribing Information
40.How should benzodiazepine use affect buprenorphine treatment?
Benzodiazepines and other central nervous system depressants increase the risk of sedation, respiratory depression, overdose, and death with buprenorphine. Nevertheless, treatment for opioid use disorder should not be categorically denied solely because a patient uses these substances. Assess intoxication, coordinate prescribing, educate about interactions, and increase monitoring or adjust the care setting when needed. Risk management should address the combination directly while preserving access to effective treatment rather than imposing an unsupported blanket exclusion.
Apply it
A patient benefiting from buprenorphine discloses prescribed benzodiazepine use. Review sedation and overdose risks, coordinate with the prescriber, and develop a monitoring and medication plan instead of automatically discharging the patient or abruptly stopping either treatment.
Common pitfall: Ignoring the interaction is unsafe, but categorical denial of opioid treatment also creates risk. Physical benzodiazepine dependence additionally makes abrupt discontinuation potentially dangerous.
DailyMed — Buprenorphine Sublingual Tablets Prescribing Information · Joint Clinical Practice Guideline on Benzodiazepine Tapering
41.Why is agonist treatment preferred to withdrawal during pregnancy?
For pregnant patients with opioid use disorder, methadone or buprenorphine treatment is recommended and is preferable to medically supervised withdrawal because withdrawal is associated with substantial relapse risk. Relapse can reintroduce overdose risk and unstable exposure. Care should integrate prenatal services, addiction treatment, and attention to co-occurring needs. A pregnancy diagnosis therefore calls for coordinated treatment planning rather than reflexive cessation of effective medication because the fetus has been exposed to an opioid.
Apply it
A pregnant patient stable on methadone asks to stop immediately to prevent all fetal exposure. Explain the relapse concerns and arrange coordinated prenatal and addiction care while discussing the benefits and risks of continuing evidence-based treatment.
Common pitfall: Avoid equating less prescribed opioid exposure with a safer overall pregnancy. Relapse, overdose, disrupted care, and unstable substance exposure also affect maternal and fetal outcomes.
42.Why should opioid-exposed newborns be monitored after birth?
Infants with prenatal opioid exposure should be monitored by pediatric clinicians for neonatal withdrawal and other relevant needs. Withdrawal may occur after exposure to appropriately prescribed treatment and does not establish that maternal care was inappropriate. Anticipatory coordination allows the birth team to recognize symptoms and provide suitable care. This neonatal planning complements effective maternal treatment; it should not be used as a reason to withhold recommended medication for opioid use disorder during pregnancy.
Apply it
A patient receiving buprenorphine is approaching delivery. Coordinate with obstetric and pediatric teams so the newborn receives appropriate observation, while explaining that possible neonatal withdrawal does not negate the reasons for maintaining effective maternal treatment.
Common pitfall: Neonatal withdrawal is an expected possibility requiring care, not proof of maternal misconduct. Do not use its possibility alone to justify destabilizing effective pregnancy treatment.
43.When does combination nicotine replacement make sense?
Combining a nicotine patch with gum or lozenges addresses two different patterns of need. The patch supplies steady nicotine through the day, while a short-acting product helps with breakthrough cravings. Persistent cue-related urges despite adequate background coverage therefore need not mean the entire approach has failed. Review adherence and correct product use, then tailor the combination to the patient's symptoms and circumstances alongside behavioral support for the smoking cessation attempt.
Apply it
A patient using a patch has good morning control but strong cravings during usual smoking breaks. Consider adding gum or lozenges for those episodes after reviewing technique, rather than interpreting every breakthrough craving as failure of nicotine replacement.
Common pitfall: Two nicotine products are not automatically inappropriate duplication. A long-acting patch and a short-acting product can serve complementary roles when used correctly for cessation.
44.When should worsening vomiting during cannabinoid treatment change the plan?
Dronabinol can paradoxically worsen nausea, vomiting, or abdominal pain despite its antiemetic use. The label describes a pattern resembling cannabinoid hyperemesis in chronic THC users. Ask about prescribed and other cannabinoid exposure, dose changes, and the relationship between treatment and symptoms. Assess dehydration and electrolyte disturbance, evaluate other causes, and consider reducing or discontinuing dronabinol when symptoms worsen. Increasing the dose automatically can perpetuate exposure to a drug contributing to the complaint.
Apply it
A patient receiving dronabinol develops recurrent vomiting that becomes more severe during treatment. Review the complete cannabinoid history, assess volume status and metabolic consequences, and reconsider the medication while investigating alternative causes rather than assuming the symptoms reflect undertreated nausea.
Common pitfall: An antiemetic indication does not exclude drug-related vomiting. A temporal association warrants evaluation but does not independently establish the diagnosis or exclude another urgent abdominal or systemic illness.
45.Why is contingency management central to stimulant treatment?
Contingency management provides tangible reinforcement linked to specified treatment behaviors or outcomes, such as attendance or verified abstinence. The ASAM/AAAP guideline identifies it as a primary component of stimulant use disorder treatment because of its evidence base. Effective design requires a clear target, reliable verification, and a consistent reinforcement plan. It is a structured behavioral intervention, distinct from nonspecific praise, punishment, or making all clinical care conditional on immediate abstinence.
Apply it
A program wants to reward verified stimulant abstinence using a predefined incentive schedule and reliable testing. This is contingency management when the target and reinforcement are explicit, and it can be integrated with other recommended behavioral treatment.
Common pitfall: Contingency management is not merely giving occasional rewards. An unclear target or inconsistent delivery weakens the connection between the desired behavior and its reinforcing consequence.
ASAM/AAAP — Clinical Practice Guideline on the Management of Stimulant Use Disorder
46.How does cognitive behavioral therapy address stimulant use?
Cognitive behavioral therapy helps patients identify relationships among situations, thoughts, emotions, and substance use, then practise alternative responses. For stimulant use disorder, it can accompany contingency management and other treatment. Its distinguishing mechanism is skill development: recognizing triggers, examining expectations, solving problems, and rehearsing coping responses. This differs from simply providing information about harms or delivering incentives, although those approaches may complement the same overall treatment plan.
Apply it
A patient repeatedly uses stimulants after believing that exhaustion makes work impossible without them. Map the triggering situation, expectation, and behavior, then rehearse alternative coping and problem-solving responses as part of a structured treatment plan.
Common pitfall: Explaining stimulant risks is education, but it is not a complete cognitive behavioral intervention. The patient needs opportunities to identify patterns and practise alternative responses.
ASAM/AAAP — Clinical Practice Guideline on the Management of Stimulant Use Disorder
47.How should stimulant-associated psychosis be evaluated?
Psychotic symptoms in a person using stimulants require assessment of severity, immediate safety, intoxication or withdrawal, medical contributors, and possible independent psychiatric illness. A temporal relationship to stimulant exposure is informative but does not justify dismissing persistent or dangerous symptoms. The ASAM/AAAP guideline recommends treating stimulant-induced psychotic symptoms with an antipsychotic while tailoring urgency and duration to the clinical presentation. Stabilization and assessment should proceed together rather than awaiting certainty about every causal contribution.
Apply it
A patient with recent stimulant use has persecutory beliefs and behavior that creates immediate danger. Arrange an appropriate acute care setting, evaluate medical and psychiatric causes, and treat psychotic symptoms rather than postponing intervention until prolonged abstinence establishes the diagnosis.
Common pitfall: Do not assume every psychotic symptom is transient intoxication. Equally, a stimulant exposure history alone does not establish a permanent primary psychotic disorder.
ASAM/AAAP — Clinical Practice Guideline on the Management of Stimulant Use Disorder
48.How should an established benzodiazepine taper respond to withdrawal?
A benzodiazepine taper should be individualized and adjusted according to symptoms, risks, and patient response. Abrupt discontinuation in a physically dependent patient can cause severe withdrawal, including seizures. If clinically significant symptoms emerge during a planned taper, consider slowing or pausing it while reassessing contributing conditions. The goal is a safer reduction process, not adherence to an inflexible calendar. Shared decisions and continuing treatment of the underlying indication support a tolerable course.
Apply it
A patient develops persistent tremor, insomnia, and distress after the latest planned reduction. Reassess withdrawal and other causes, then consider holding or slowing the taper rather than automatically making the next scheduled reduction despite worsening symptoms.
Common pitfall: A written schedule is a starting plan, not a mandate. Forcing reductions despite significant withdrawal can increase risk and undermine the patient's ability to continue.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
49.How should an unexpected presumptive drug test be handled?
Presumptive drug tests can yield unexpected results because of cross-reactivity, detection limitations, timing, or specimen issues. Discuss the result nonjudgmentally, review medications and exposure history, and obtain definitive testing when the result is disputed or will drive a consequential decision. A test result is one piece of clinical information rather than a complete diagnosis. Interpretation should consider what the assay actually detects and avoid punitive decisions based on unconfirmed assumptions.
Apply it
A stable patient's screening immunoassay unexpectedly detects a substance the patient denies using. Review possible explanations and request definitive testing before making a major treatment change based solely on the disputed presumptive result in this encounter.
Common pitfall: Presumptive does not mean certain. Neither automatic acceptance nor automatic dismissal is adequate when the result conflicts with the clinical picture and carries important consequences.
ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine
50.When can suicide risk increase during stimulant care?
Suicidality may increase as stimulant intoxication wanes and during acute withdrawal. Assessment must therefore continue beyond the period of obvious stimulation or agitation. Evaluate suicidal thoughts, intent, available means, psychosis, mood symptoms, and the patient's ability to remain safe, using an appropriate care setting when risk requires it. A calmer presentation is not sufficient evidence of improved psychiatric safety, and co-occurring symptoms should be addressed alongside the substance use disorder.
Apply it
A patient becomes less agitated after stimulant intoxication but begins expressing hopelessness and a wish to die. Reassess suicide risk directly and arrange the necessary level of psychiatric support rather than interpreting reduced motor activity as recovery.
Common pitfall: Visible calming and reduced intoxication do not establish safety. Withdrawal-related distress or emerging depression can become clearer precisely when the initial agitation is resolving.
ASAM/AAAP — Clinical Practice Guideline on the Management of Stimulant Use Disorder
51.How does naltrexone change acute pain planning?
Naltrexone can block opioid analgesia, so clinicians treating acute pain need to know that it is being taken. The label describes approaches including regional analgesia, nonopioid analgesics, and other carefully selected measures. If opioid analgesia is required in an emergency, the blockade and potential respiratory risks require close monitoring by appropriately trained clinicians. Patients should not attempt to overcome the blockade themselves, and treatment planning should anticipate pain needs when possible.
Apply it
A patient taking naltrexone presents for urgent treatment of a painful injury. Tell the acute care team about the antagonist, develop an appropriate analgesic plan, and avoid advising the patient to increase opioid doses independently until relief occurs.
Common pitfall: Poor opioid response does not automatically mean low pain severity. Antagonist blockade can explain it, while attempts to override blockade can create serious toxicity.
DailyMed — Naltrexone Hydrochloride Tablets Prescribing Information
Ethical, legal, and liability issues (17)15%
52.What makes informed consent more than a signature?
Informed consent is a communication process supporting a voluntary decision, not merely a completed form. AMA guidance calls for assessing the patient's ability to understand, explaining the diagnosis when known, describing the purpose and burdens of proposed interventions, and discussing alternatives, including forgoing treatment. The physician should document the discussion and decision. In addiction care, disagreement with the clinician does not itself show incapacity or justify bypassing the patient's participation.
Apply it
A patient signs a treatment form but cannot explain the proposed medication's purpose or alternatives. Revisit the discussion in understandable language and assess comprehension rather than treating the signature as sufficient evidence of an informed decision.
Common pitfall: Documentation supports the process but cannot replace understanding and voluntariness. A signed form alone does not establish that relevant options and consequences were meaningfully discussed.
53.How should capacity be assessed when a patient declines treatment?
A patient's decision-making ability should be assessed in relation to the proposed intervention and current clinical state. AMA guidance emphasizes the ability to understand relevant information and treatment implications and to make an independent, voluntary decision. Substance use history alone does not answer that question. Explore comprehension, potentially reversible impairment, and coercion while explaining alternatives. A refusal that differs from the physician's preferred choice may still be an informed and autonomous decision.
Apply it
A patient with alcohol use disorder accurately explains treatment options and consequences but declines the recommended medication. Assess understanding and voluntariness directly instead of concluding that the diagnosis or disagreement automatically removes the ability to decide.
Common pitfall: An unwise choice is not synonymous with incapacity. Conversely, a coherent preference should not end assessment when delirium or another impairment undermines meaningful understanding.
54.When does emergency treatment proceed without prior consent?
AMA guidance permits urgently needed treatment without prior informed consent when an emergency requires immediate action, the patient cannot participate, and a surrogate is unavailable. The exception is tied to urgency and inability to obtain a decision, not simply to a substance-related diagnosis. Inform the patient or surrogate at the earliest opportunity and obtain consent for continuing treatment when possible. Professional ethics guidance should be distinguished from jurisdiction-specific legal requirements.
Apply it
An unconscious patient requires immediate lifesaving intervention, cannot communicate, and has no available surrogate. Begin necessary emergency treatment, then explain what occurred and address consent for ongoing care when the patient or an appropriate surrogate can participate.
Common pitfall: Emergency authority is not continuing permission for every later intervention. Once immediate urgency resolves and participation becomes possible, restore the ordinary informed-consent process.
55.When should a physician decline a patient's gift?
AMA guidance advises declining gifts that are disproportionately large or appear intended to secure preferential care. Consider the gift's value, meaning, circumstances, and effect on the therapeutic relationship. A modest expression of gratitude may raise different concerns from a payment tied to access or prescribing. The core ethical issue is whether acceptance would compromise professional judgment, create an expectation of special treatment, or exploit the patient's circumstances rather than preserve equitable care.
Apply it
A patient offers an expensive gift while requesting priority appointments and exceptions to prescribing boundaries. Decline the gift respectfully and explain that clinical decisions and access rules must remain based on appropriate care rather than personal rewards.
Common pitfall: Gratitude does not make every gift acceptable. The request attached to a gift can create an ethical problem even when the patient presents it warmly.
56.Why are industry cash gifts ethically problematic?
AMA guidance states that physicians should decline cash gifts from industry. Such gifts can create conflicts between professional judgment and financial influence, including perceived obligations around prescribing. Renaming a payment an educational token does not resolve the concern when it is simply a personal cash benefit. Evaluate other arrangements according to their actual purpose and conditions, recognizing that legitimate compensation for services is a different category from an unrestricted gift.
Apply it
A manufacturer offers a physician a personal cash payment with no actual service required and describes it as appreciation for educational interest. Decline the gift rather than treating the label as evidence that the arrangement is ethically acceptable.
Common pitfall: An educational explanation does not convert a personal cash gift into acceptable support. Assess what is actually provided, to whom, and in return for what.
AMA Code of Medical Ethics — Gifts to Physicians from Industry
57.Which records fall within the federal Part 2 framework?
Federal 42 CFR Part 2 protects qualifying substance use disorder records associated with federally assisted programs meeting its applicability requirements. It is not a rule automatically attached to every mention of substance use in every medical record. Determine whether the program and records are covered before selecting a disclosure pathway. HIPAA and other applicable protections may also matter. The initial decision is therefore about legal scope, followed by the conditions governing a proposed use or disclosure.
Apply it
A general medical office receives a request involving substance use information. First determine whether the information is a covered Part 2 record and how it was obtained, rather than assuming that the subject matter alone resolves every disclosure requirement.
Common pitfall: Neither 'all substance information is Part 2' nor 'ordinary health privacy rules are sufficient everywhere' is reliable. Program status and record provenance can change the analysis.
HHS — Understanding Confidentiality of SUD Patient Records · HHS — Fact Sheet: 42 CFR Part 2 Final Rule
58.What does a single Part 2 TPO consent authorize, and which notes require separate consent?
The 2024 final rule permits a single consent for future treatment, payment, and health care operations uses and disclosures. HIPAA covered entities and business associates receiving records under it may redisclose as HIPAA permits, subject to Part 2 limits. Separately maintained SUD counseling notes have additional protection: qualifying clinician notes analyzing counseling conversations require separate consent and cannot be disclosed using broad TPO consent. These notes are distinct from ordinary treatment-record documentation; an entry does not become a protected counseling note merely because it concerns SUD treatment.
Apply it
A program has valid TPO consent for coordinating medication care and billing. A request also seeks the clinician's separately maintained analysis of counseling conversations. Evaluate those qualifying counseling notes under their separate-consent requirement rather than including them automatically with the ordinary treatment record.
Common pitfall: Single consent does not authorize every record or purpose. Separate protection depends on qualifying counseling-note content and separate maintenance, not simply on the presence of sensitive information.
59.Why does routine Part 2 consent not authorize use against a patient?
The Part 2 final rule preserves special restrictions on using or disclosing records in civil, criminal, administrative, or legislative proceedings against the patient. A routine treatment, payment, and health care operations consent does not supply unrestricted authorization for those proceedings. Applicable requirements include specific patient consent or a qualifying court order under the rule. Distinguish a request that supports care from one seeking evidence against the patient, even when the requester already possesses related information.
Apply it
A recipient of records under a treatment consent is asked to provide them for a proceeding against the patient. Do not rely on the routine consent; evaluate the specific Part 2 authorization and court-order requirements for that use.
Common pitfall: Possession of records does not establish permission for every later use. A routine care disclosure cannot automatically be repurposed as evidence against the patient.
60.When did compliance with the revised Part 2 rule become required?
HHS states that the 2024 Part 2 final rule became effective April 16, 2024, with compliance required by February 16, 2026. Effective and compliance dates serve different functions: legal effectiveness did not mean every operational change had to be completed immediately. For an October 2026 federal Part 2 scenario, the compliance deadline has passed. Apply the revised framework rather than assuming the transition period remains open, while considering other applicable legal requirements.
Apply it
In October 2026, a covered program argues that the 2024 revisions are still optional because implementation was delayed. Compare the scenario date with February 16, 2026; the stated federal compliance deadline has already passed.
Common pitfall: Do not interchange publication, effective, and compliance dates. A transition period can postpone required implementation, but it does not continue indefinitely after the stated deadline.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official outline as the complete scope. Allocate study time approximately 25% to foundations, 20% to epidemiology and prevention, 40% to clinical management, and 15% to ethics and law.
- Prioritize alcohol and nicotine while integrating opioids, sedatives, stimulants, and cannabinoids. Add dedicated coverage of the outline's less heavily weighted substances and nonsubstance addiction beyond this selective guide.
- Practise distinctions that change decisions: screening versus diagnosis, dependence versus disorder, current withdrawal severity versus future risk, receptor affinity versus activation, presumptive versus definitive testing, and ethics guidance versus binding law.
- Connect pharmacology to treatment boundaries: opioid exposure and abstinence intervals before naltrexone, renal clearance and dose selection before acamprosate, withdrawal readiness before standard buprenorphine initiation, and sedative interactions during opioid treatment.
- Calculate incidence, prevalence, relative risk, and absolute differences from clearly defined denominators and follow-up periods. Interpret population estimates using their stated year, population, and case definition, and distinguish a prevalence estimate from evidence of a trend.
- Apply federal Part 2 requirements to a specified date, covered record, disclosure purpose, and consent pathway. Distinguish ordinary treatment records, separately maintained SUD counseling notes, and requests for proceedings against the patient.
A practical preparation plan
1. Map the complete scope
Read the official numbered outline and mark topics covered by this guide. Build a separate plan for remaining substance targets, co-occurring conditions, pain care, and other presentations so that strong performance on these selective materials does not conceal scope gaps.
2. Build mechanisms into decisions
For each medication, state its receptor action or physiological role, intended clinical use, decisive contraindication or caution, and an observation that would change the plan. Rehearse these links for alcohol, nicotine, opioid, sedative, stimulant, and cannabinoid scenarios.
3. Rehearse assessment before treatment
Begin an alcohol case with a validated screen, then assess the drinking pattern, eleven AUD symptoms, severity, withdrawal risk, and consequences. Choose brief intervention or continuing treatment accordingly. For acute withdrawal and psychiatric cases, identify immediate danger, exposure timing, prior complications, alternative diagnoses, monitoring needs, and the appropriate setting.
4. Practise quantitative and legal interpretation
Calculate epidemiological measures without looking at formulas, then explain their limits. For confidentiality cases, identify jurisdiction, date, Part 2 applicability, record type, purpose, and required authorization before deciding whether disclosure is permitted.
5. Use the drills to locate reasoning gaps
Complete the 20 questions, explain why every alternative is less appropriate, and review the corresponding source when the distinction remains unclear. Revisit flashcards using active recall. Treat results as feedback on these topics rather than a pass prediction.
6. Integrate related clinical problems
Combine topics in short cases: alcohol withdrawal with delirium, opioid treatment with benzodiazepine dependence, smoking cessation with breakthrough cravings, or stimulant withdrawal with emerging suicidality. Explain which new finding changes the diagnosis, treatment, monitoring, or setting.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABPM — Addiction Medicine
- ABPM — Exam Content
- ABPM — Addiction Medicine Content Outline
- ABPM — 2026 Program Director Guide
- ABPM — Addiction Medicine Practice Analysis Survey Underway
- NIAAA — Alcohol Flush Reaction
- NIAAA — Alcohol Metabolism
- NIAAA — Genetics and Alcohol Use Disorder
- NIAAA — The Cycle of Alcohol Addiction
- DailyMed — Buprenorphine Sublingual Tablets Prescribing Information
- DailyMed — Dronabinol Capsules Prescribing Information
- DailyMed — Naltrexone Hydrochloride Tablets Prescribing Information
- DailyMed — Campral Prescribing Information
- CDC — How Quit Smoking Medicines Work
- CDC — How to Combine Quit Smoking Medicines
- CDC — Principles of Epidemiology, Measures of Association
- CDC — Principles of Epidemiology, Morbidity Frequency Measures
- USPSTF — Tobacco Use in Children and Adolescents: Primary Care Interventions
- CDC — Syringe Services Programs: A Technical Package
- ASAM — Clinical Practice Guideline on Alcohol Withdrawal Management
- ASAM/AAAP — Clinical Practice Guideline on the Management of Stimulant Use Disorder
- Joint Clinical Practice Guideline on Benzodiazepine Tapering
- ASAM — Appropriate Use of Drug Testing in Clinical Addiction Medicine
- ASAM — Opioid Use Disorder in Pregnancy
- AMA Code of Medical Ethics — Informed Consent
- AMA Code of Medical Ethics — Gifts from Patients
- AMA Code of Medical Ethics — Gifts to Physicians from Industry
- HHS — Understanding Confidentiality of SUD Patient Records
- HHS — Fact Sheet: 42 CFR Part 2 Final Rule
- Alcohol Use Disorder: From Risk to Diagnosis to Recovery | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Screen and Assess: Use Quick, Effective Methods | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- bzd-tapering-document---final-approved-version-for-distribution-02-28-25.pdf
- Federal Register :: Request Access
- Principles of Epidemiology | Lesson 1 - Section 7
- 1.2.8.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.